Specialty Pharmacy

Top news of the week from Specialty Pharmacy Times.

Matthew Malachowski, PharmD, BCPS, supervisor of specialty pharmacy services at UAB Health System, discusses opportunities to improve the patient experience.

Most Americans have never heard of hereditary transthyretin amyloidosis (hATTR), which speaks to its very low incidence rate in the population.

The study authors believe that the modification of teriflunomide and the development of new DHODH inhibitors is urgent for drug-resistant epilepsy patients

Partnerships like the UC College of Pharmacy and Walgreens offer opportunities for experience with complex disease states, such as cancer, multiple sclerosis, HIV, and Crohn’s disease, that many students will see after they graduate.

The oncology drug pipeline has experienced rapid growth over the past decade, driven by innovation in cell therapies, immunotherapy, and precision medicine, according to a specialty pipeline update presentation at the Asembia Specialty Pharmacy Summit 2019.

Co-pay accumulator programs are the latest cost management initiative resulting from the constant push and pull between payers, pharmacy benefit managers, and manufacturers to reduce drug spend.

Mouthwash containing diphenhydramine, lidocaine, and antacids found to significantly reduce pain from oral mucositis in patients with head and neck cancer administered chemotherapy.

Treatment for inflammatory bowel disease has the best outcomes when patients partner with their medical teams.

Why health system specialty pharmacies are uniquely positioned to provide valuable data and superior care to the patients they serve.

Amber Draper, PharmD, BCOP, clinical pharmacist at Winship Cancer Institute discussed how biomarkers are used to make informed decisions in colorectal cancer treatment.

The specialty lite platform leverages the current infrastructure of specialty pharmacies with efficient services and emerging technological solutions that focus on ensuring prescription fulfillment with economic feasibility.

This drug was previously approved, in 2017, to treat HCV in adults.

The preclinical data was presented by Beam Therapeutics, Monday at the American Society of Gene and Cell Therapy (ASGCT) 22nd Annual Meeting in Washington, DC.

Study finds cannabidiol may act as a Trojan horse to transport molecules into the brain.

Experts emphasized the need for clinicians to use every available tool when patients need PCSK9 inhibitors but face access barriers.

During a session on Monday at Asembia’s Specialty Pharmacy Summit 2019, experts discussed specialty pharmacy’s potential to improve outcomes for patients with pulmonary arterial hypertension.

Diagnostic delay tends to be a challenge for patients with hereditary angioedema, a rare but serious condition affecting 1 in 50,000 individuals.

During the week of the summit, you’ll find shows unique to the city that are sure to make lifelong memories.

Alison Duffy, PharmD, BCOP, from UM Greenebaum Comprehensive Cancer Center, talks about some of the emerging agents in the chronic lymphocytic leukemia treatment landscape.

This new offering provides an end-to-end digital prescription process with nationwide access through more than 25,000 retail pharmacies.

Study demonstrates safety of oral immunotherapy for peanut allergy in large group of preschool-aged children.

Lisa Holle, PharmD, BCOP, FHOPA, associate clinical professor at the University of Connecticut discusses the evolving role of genomics in the treatment of prostate cancer.

Check back daily for our coverage of the Asembia Specialty Pharmacy Summit this week.

Adults who experience a heart attack or stroke have an approximately 1 in t3 chance to have another cardiovascular event.

This is the first time that the FDA has approved a treatment for pediatric patients with SLE. Belimumab has been approved for use in adult patients since 2011. GSK’s application for belimumab use in pediatric patients was granted the FDA’s Priority Review designation.

Samsung Bioepis’ etanercept-ykro (Eticovo) was approved to treat all of the indications of the reference product, including rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.

The COAST-X clinical trial program is evaluating ixekizumab across various population subsets of patients with axial spondyloarthritis.

Top news of the day from across the health care landscape.

Top news of the week from Specialty Pharmacy Times.